Kiniksa Pharmaceuticals, Ltd. KNSA 深 滬
已收盤 08-08 16:00:00 美东时间
32.15
-0.960
-2.90%
華盛通- 最 高33.68
- 今 開33.41
- 成交量 67.59万股
- 最 低 31.78
- 昨 收 33.11
- 總市值 23.46亿
- 52周最高 33.98
- 市盈率 靜 --
- 換手率 0.93%
- 52周最低 17.82
- 委 比 -94.53%
- 總股本 7297.10万
- 歷史最高 33.98
- 量 比 0.76
- 振 幅 5.74%
- 歷史最低 5.01
- 每 手 1
- 風險率 3.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多What to Expect from Kymera Therapeutics's Earnings
Kymera Therapeutics (NASDAQ:KYMR) is gearing up to announce its quarterly earni...
08-08 23:01
Recursion Pharmaceuticals Earnings Preview
Recursion Pharmaceuticals (NASDAQ:RXRX) is gearing up to announce its quarterly...
08-05 01:05
Why CommScope Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
Shares of CommScope Holding Company, Inc. (NASDAQ:COMM) rose sharply in pre-mar...
08-04 18:55
美股大行评级 | 潜在涨幅36%！花旗上调Coinbase目标价升至505美元；摩根大通维持迪士尼"超配"评级，目标价升至138美元
今日重点评级关注：花旗：维持Apellis Pharmaceuticals"买入"评级，目标价从41美元升至46美元；杰富瑞：维持Kiniksa Pharmaceuticals"买入"评级，目标价从45美元升至54美元
07-30 09:36
Kiniksa Pharmaceuticals Reports Strong ARCALYST Growth
Kiniksa Pharmaceuticals Ltd. Class A (($KNSA)) has held its Q2 earnings call. R...
07-30 08:38
Earnings Scheduled For July 29, 2025
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is projected to repor...
07-29 16:32
Earnings Preview: Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals (NASDAQ:KNSA) is set to give its latest quarterly earni...
07-29 02:01
Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025
Kiniksa Pharmaceuticals International, plc will host a conference call and live webcast on July 29, 2025, at 8:30 a.m. ET to discuss its second quarter 2025 financial results and recent portfolio execution. The webcast will be available on the company’s website, and participants can register via the provided link for telephone access. A replay will be accessible within 48 hours. Kiniksa is a biopharmaceutical company focused on developing novel t...
07-24 20:01
Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $42
Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $30 to $42.
07-09 21:14
Kiniksa Pharmaceuticals Unveils Phase 2/3 Trial Plans
The latest update is out from Kiniksa Pharmaceuticals ( ($KNSA) ). On June 5, 2...
06-05 19:28
